Translate Bio (Translate Bio) Interest Expense : $0.0 Mil (TTM As of Jun. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Translate Bio's interest expense for the three months ended in Jun. 2021 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2021 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Translate Bio's Operating Income for the three months ended in Jun. 2021 was $ 20.3 Mil. Translate Bio's Interest Expense for the three months ended in Jun. 2021 was $ 0.0 Mil. GuruFocus does not calculate Translate Bio's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Translate Bio Interest Expense Historical Data

The historical data trend for Translate Bio's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Interest Expense Chart

Translate Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Expense

Translate Bio Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Interest Expense	Get a 7-Day Free Trial														-	-	-	-	-

Translate Bio Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Translate Bio (NAS:TBIO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Translate Bio's Interest Expense for the three months ended in Jun. 2021 was $0.0 Mil. Its Operating Income for the three months ended in Jun. 2021 was $20.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2021 was $46.2 Mil.

Translate Bio's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as

GuruFocus does not calculate Translate Bio's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Translate Bio Inc has enough cash to cover all of its debt. Its financial situation is stable.

Translate Bio (Translate Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

http://www.translate.bio

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Executives

Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr	director, officer: Chief Executive Officer, other: President	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess	officer: Chief Operating Officer, CLO, other: Secretary	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc.	10 percent owner	300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma	10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch	director
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier	officer: Chief Medical Officer	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109